scPharmaceuticals Q4 2022 Earnings Report $3.30 +0.05 (+1.54%) (As of 10:39 AM ET) Earnings HistoryForecast scPharmaceuticals EPS ResultsActual EPS-$0.30Consensus EPS -$0.42Beat/MissBeat by +$0.12One Year Ago EPSN/AscPharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AscPharmaceuticals Announcement DetailsQuarterQ4 2022Date3/22/2023TimeN/AConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSCPH Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by This drone stock is setting up to transform medical supply delivery (Ad)Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.Click here to see how a new partnership could catapult this drone suppliers' growth scPharmaceuticals Earnings HeadlinesTD Cowen Sticks to Its Buy Rating for scPharmaceuticals (SCPH)December 12, 2024 | markets.businessinsider.comCraig-Hallum Issues a Buy Rating on scPharmaceuticals (SCPH)December 11, 2024 | markets.businessinsider.comThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.December 18, 2024 | The Tomorrow Investor (Ad)ScPharmaceuticals Stock Falls After Noting Possible FDA Submission DelayDecember 11, 2024 | marketwatch.comEarnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their ForecastsNovember 16, 2024 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | insidermonkey.comSee More scPharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like scPharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on scPharmaceuticals and other key companies, straight to your email. Email Address About scPharmaceuticalsscPharmaceuticals (NASDAQ:SCPH), a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.View scPharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
